SuperGen, Inc. To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference

DUBLIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that James S. Manuso, Ph.D., President and Chief Executive Officer is scheduled to present at The 8th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, on Tuesday, February 14, 2006 at 3:00 p.m. ET. Dr. Manuso will provide a brief corporate overview and discuss the Company's recent progress, including the Company's recently announced agreement to acquire Montigen Pharmaceuticals.

A live webcast of Dr. Manuso's presentation on February 14, 2006 will be available on the Investor Relations section of the Company's website at The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's product portfolio includes: Nipent(R) (pentostatin for injection); Mitomycin (generic brand of Mutamycin(R)); and SurfaceSafe(R) cleaner.

For more information about SuperGen, please visit Contacts: Timothy L. Enns Sharon Weinstein SuperGen, Inc. Noonan Russo Tel: (925) 560-0100 x111 Tel: (212) 845-4271 E-mail: E-mail:

SuperGen, Inc.

CONTACT: Timothy L. Enns of SuperGen, Inc., +1-925-560-0100 x111,; or Sharon Weinstein of Noonan Russo, +1-212-845-4271,

Back to news